Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:CRDF NASDAQ:FRMM NASDAQ:NCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$8.04-7.3%$9.95$3.92▼$19.15$78.12M0.0879,028 shs202,776 shsCRDFCardiff Oncology$1.31-3.0%$1.49$1.16▼$4.56$92.30M1.441.19 million shs664,517 shsFRMMForum Markets$6.80+4.9%$5.08$1.76▼$174.60$86.77M1.37334,954 shs627,233 shsNCELNLS Pharmaceutics$3.98-0.5%$3.45$1.83▼$28.03$21.38M0.9333,952 shs28,030 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-7.27%-21.64%-22.77%+53.44%-13.55%CRDFCardiff Oncology-2.96%-2.96%-14.94%-22.94%-68.28%FRMMForum Markets+4.94%+19.30%+27.10%+219.25%+679,999,900.00%NCELNLS Pharmaceutics-0.50%-0.75%+23.22%+59.20%-81.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$8.04-7.3%$9.95$3.92▼$19.15$78.12M0.0879,028 shs202,776 shsCRDFCardiff Oncology$1.31-3.0%$1.49$1.16▼$4.56$92.30M1.441.19 million shs664,517 shsFRMMForum Markets$6.80+4.9%$5.08$1.76▼$174.60$86.77M1.37334,954 shs627,233 shsNCELNLS Pharmaceutics$3.98-0.5%$3.45$1.83▼$28.03$21.38M0.9333,952 shs28,030 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-7.27%-21.64%-22.77%+53.44%-13.55%CRDFCardiff Oncology-2.96%-2.96%-14.94%-22.94%-68.28%FRMMForum Markets+4.94%+19.30%+27.10%+219.25%+679,999,900.00%NCELNLS Pharmaceutics-0.50%-0.75%+23.22%+59.20%-81.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.5018.16% UpsideCRDFCardiff Oncology 2.17Hold$7.50472.52% UpsideFRMMForum Markets 2.50Moderate Buy$10.0047.06% UpsideNCELNLS Pharmaceutics 2.00Hold$23.00477.89% UpsideCurrent Analyst Ratings BreakdownLatest NCEL, FRMM, ATRA, and CRDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026NCELNLS Pharmaceutics LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$23.006/30/2026FRMMForum Markets Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/29/2026NCELNLS Pharmaceutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)6/11/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)6/3/2026CRDFCardiff Oncology Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$2.006/1/2026CRDFCardiff Oncology TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/1/2026CRDFCardiff Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/29/2026FRMMForum Markets Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/18/2026ATRAAtara Biotherapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$5.00 ➝ $9.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.60$4.52 per share1.78($5.34) per share-1.51CRDFCardiff Oncology$590K151.80N/AN/A$0.67 per share1.96FRMMForum Markets$9.41M9.68N/AN/A$12.59 per share0.54NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M-$0.67N/A5.74N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)CRDFCardiff Oncology-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)FRMMForum Markets-$450.52M-$36.07N/A42.50N/AN/A-242.09%-135.46%N/ANCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/ALatest NCEL, FRMM, ATRA, and CRDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026ATRAAtara Biotherapeutics-$0.3150N/AN/AN/A$0.55 millionN/A8/4/2026Q2 2026CRDFCardiff Oncology-$0.17N/AN/AN/A$0.06 millionN/A5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million5/14/2026Q1 2026FRMMForum MarketsN/A-$3.64N/A-$3.58N/A$2.86 million5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A2.162.16CRDFCardiff OncologyN/A3.273.27FRMMForum Markets0.156.196.19NCELNLS PharmaceuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CRDFCardiff Oncology16.29%FRMMForum Markets4.07%NCELNLS PharmaceuticsN/AInsider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%CRDFCardiff Oncology8.50%FRMMForum Markets25.20%NCELNLS Pharmaceutics16.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataCRDFCardiff Oncology2068.37 million62.56 millionOptionableFRMMForum Markets713.39 million10.02 millionN/ANCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableNCEL, FRMM, ATRA, and CRDF HeadlinesRecent News About These CompaniesNLS Pharmaceutics (NASDAQ:NCEL) Trading Up 5.5% - What's Next?July 9, 2026 | americanbankingnews.comNewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory BoardJuly 8, 2026 | globenewswire.comNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 DiabetesJuly 1, 2026 | globenewswire.comNewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformJune 15, 2026 | globenewswire.comNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesMay 27, 2026 | globenewswire.comNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026April 30, 2026 | globenewswire.comMichel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) StockApril 30, 2026 | insidertrades.comNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceApril 20, 2026 | globenewswire.comNewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingApril 1, 2026 | globenewswire.comNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesMarch 9, 2026 | prnewswire.comNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization StrategyFebruary 12, 2026 | prnewswire.comNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering ConferencesJanuary 29, 2026 | prnewswire.comNewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune SuppressionJanuary 12, 2026 | prnewswire.comNewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory BoardJanuary 5, 2026 | prnewswire.comNewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in ChinaDecember 11, 2025 | prnewswire.comNewCelX Appoints EY as New Auditor Following MergerNovember 20, 2025 | tipranks.comNewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstituteNovember 17, 2025 | prnewswire.comNewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory BoardNovember 6, 2025 | prnewswire.comNewcelX Ltd.November 5, 2025 | cnn.comNewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.November 4, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCEL, FRMM, ATRA, and CRDF Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$8.04 -0.63 (-7.27%) As of 07/14/2026 04:00 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Cardiff Oncology NASDAQ:CRDF$1.31 -0.04 (-2.96%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.34 +0.03 (+2.21%) As of 07/14/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Forum Markets NASDAQ:FRMM$6.80 +0.32 (+4.94%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$6.78 -0.01 (-0.22%) As of 07/14/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.NLS Pharmaceutics NASDAQ:NCEL$3.98 -0.02 (-0.50%) As of 07/14/2026 04:00 PM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
